Kornimate/medical-research-clean huggingface dataset:
bevacizumab, idarubicin, and cytarabine in treating patients with blast phase chronic myelogenous leukemia

Conditions: Blastic Phase Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Summary: this phase ii trial is to see if combining bevacizumab with idarubicin and cytarabine works better in treating patients who have blast phase chronic myelogenous leukemia. monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. some block the ability of cancer cells to grow and spread. others find cancer cells and help kill them or deliver cancer-killing substances to them. drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. combining monoclonal antibody therapy with chemotherapy may be an effective treatment for blast phase chronic myelogenous leukemia

primary objectives: i. determine the anti-leukemic activity of bevacizumab, idarubicin, and cytarabine in patients with blastic phase chronic myelogenous leukemia. ii. determine the toxicity profile of this regimen in these patients. iii. determine the effect of bevacizumab on angiogenesis in these patients. outline: patients receive bevacizumab iv over 90 minutes once on day -13. patients then receive bevacizumab iv over 90 minutes and idarubicin iv on days 1 and 15 and cytarabine subcutaneously (sc) once daily beginning on day 1. treatment repeats every 4 weeks for a maximum of 3 courses. patients with responding disease receive maintenance therapy comprising bevacizumab iv over 90 minutes on days 1 and 15, idarubicin iv on day 1, and cytarabine sc once daily beginning on day 1. treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * diagnosis of philadelphia chromosome-positive blastic phase chronic myelogenous leukemia (cml), defined by 1 of the following: * at least 30% blasts in peripheral blood and/or bone marrow * presence of extramedullary disease * performance status - zubrod 0-2 * at least 8 weeks * no prior coagulopathies * bilirubin no greater than 1.5 mg/dl * inr less than 2 * ptt no greater than 60 seconds * creatinine no greater than 1.5 mg/dl * creatinine clearance at least 60 ml/min * no nephrotic syndrome * no uncontrolled hypertension * no new york heart association class ii-iv heart disease * no prior thrombotic events * lvef ≥ 50% * not pregnant or nursing * fertile patients must use effective contraception * no more than 2 prior chemotherapy regimens (no more than 1 regimen containing cytarabine) for cml in blast crisis * prior hydroxyurea allowed * prior imatinib mesylate allowed * at least 10 days since prior anticoagulants * no concurrent anticoagulants
baduanjin-eight-silken-movement with self-efficacy building for patients with chronic heart failure (besmile-hf study)

Conditions: Heart Failure NYHA Class II; Heart Failure NYHA Class III; Heart Failure

Summary: chronic heart failure (chf) is a major and growing public health problem and poses economic burden on the society. there is a need for a safe, equipment-free, low-cost, and easily implemented exercise-based cardiac rehabilitation program for chf patients in china. baduanjin exercise, translated as 'eight silken movements', is one of the most common forms of traditional chinese exercise and it could have value to be integrated into a exercise-based cardiac rehabilitation program for chf patients, together with education, evaluation and consultancy. accordingly, the besmile-hf program applying the baduanjin exercise as the central component, has been developed in guangdong provincial hospital of chinese medicine which is one of the largest hospitals of chinese medicine in china. this project is to evaluate the efficacy and acceptability of besmile-hf program in patients with chf in china, and it will be based on a randomized controlled trial and a qualitative study.


Eligibility criteria:
inclusion criteria: 1. aged 18 years or above 2. diagnosed with chronic heart failure 3. clinically stable as defined as symptoms and signs that have remained generally unchanged for at least 1 month 4. nyha functional class ii or iii exclusion criteria: 1. patients who have contraindications to cardiopulmonary test 2. patients who have contraindications to exercise training 3. patients who have serious acute or chronic organic disease or mental disorders 4. history of cardiac surgery, cardiac resynchronization therapy, or intracardiac defibrillation within the previous 3 months; 5. history of cardiac arrest within 1 year; 6. history of peripartum cardiomyopathy, hyperthyroid heart disease, primary pulmonary hypertension; 7. inability to perform a bicycle stress test; 8. severe cognitive dysfunction precluding informed consent or understanding of exercise concepts; 9. current regular baduanjin or current participation in a conventional cardiac rehabilitation program 10. current participation in another trial.

Keywords: chronic heart failure exercise-based cardiac rehabilitation baduanjin
effects of low- load strengthening using different exercises modes during blood flow restriction for treating shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: purpose of the study: this study compares effects of isometric, concentric and eccentric exercises for shoulder muscles by using low load blood flow restriction training on pain, strength and function in patients with sis.

this study will be conducted at el hadra university hospital, alexandria, egypt. study design: randomized parallel groups clinical trial. participants: sixty patients of both genders with unilateral shoulder impingement syndrome, with age range from 30-40 years will be randomly assigned to 1 of 3 groups. all patients will be referred by the orthopedic surgeon who will diagnose shoulder impingement syndrome based on clinical and radiological examination. group 1: twenty patients will receive concentric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. group 2: twenty patients will receive eccentric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. group 3: twenty patients will receive isometric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. the assessment for all groups will be done at baseline and after 4 weeks.

Eligibility criteria:
inclusion criteria: age range 30-40 years. - pain localized to the proximal anterolateral shoulder region, - positive for pain on at least one of the following three impingement tests: hawkins-kennedy, neers, jobes and positive for pain on at least one of the following four tests: painful arc, drop arm test, lift off test, and resisted external rotation (fatima et al., 2021 exclusion criteria: * large, full-thickness rotator cuff tear, moderate, severe glenohumeral or acromioclavicular joint osteoarthritis. - glenohumeral joint instability including previous shoulder dislocation/subluxation. - previous shoulder fracture. - current neck pain/dysfunction with a somatic or radicular referral pattern indicative of cervical spine rather than shoulder as primary source of symptoms and/or pathology. - neurological deficits of the upper limb. - systemic inflammatory arthritic conditions (fatima et al., 2021).

Keywords: blood flow restriction/ shoulder impingement syndrome
diagnostic accuracy of seismocardiography for coronary artery disease

Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Summary: this study aims to evaluate a new, non-invasive method for detecting coronary artery disease (cad) using seismocardiography (scg) and gyrocardiography (gcg). these techniques measure small vibrations on the chest caused by the heartbeat using highly sensitive sensors. the goal is to determine whether this method, using the cardioclin device, can accurately detect cad compared to standard tests like coronary calcium scans (cac-ct), ct angiography (ccta), and invasive coronary angiography (ica). patients who are already scheduled for one of these standard tests will also undergo scg/gcg testing. the study will compare results to see if the new method provides a reliable, cost-effective, and radiation-free alternative for diagnosing cad. this research could help improve early detection of heart disease without the need for invasive procedures.


Eligibility criteria:
inclusion criteria: * aged 18 years or older. * suspected cad, based on clinical evaluation. * able to provide informed consent. exclusion criteria: * pregnant or breastfeeding women. * presence of implanted cardiac devices (e.g., pacemakers, implantable cardioverter defibrillators) that may interfere with scg/gcg signal acquisition. * severe arrhythmias that may affect signal interpretation. * inability to maintain required testing positions (supine and sitting). * medical conditions preventing informed consent (e.g., severe cognitive impairment).

Keywords: coronary artery disease seismocardiography cardioclin
comparison of apnea tolerance in two positions of patients with bmi 30-40

Conditions: General Surgery

Summary: the purpose of this study is to compare the effect of the 25° head-up position versus the 55° head-up position on tolerable apnea time (tat) after induction of general anesthesia in patients with a body mass index (bmi) of 30-40.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-iii * body mass index (bmi) of 30-40 * scheduled for an elective surgery that requires tracheal intubation exclusion criteria: * patients with abnormalities of the upper airway that require awake tracheal intubation * asthma * chronic obstructive pulmonary disease * congestive heart failure * pregnant patients

Keywords: tracheal intubation
atorvastatin plus ezetimibe on coronary plaque progression

Conditions: Coronary Artery Disease

Summary: atherosclerosis is a progressive disease. lipid lowering therapy was the standard treatment for patients with coronary artery disease. studies indicated that coronary artery plaque progression had positive relationship with the plasma cholesterol level, and could be halted or reversed by intensive statin therapy (such as 20-40 mg/d atorvastatin). ezetimibe plus statin could further lowered blood cholesterol level. here the investigators hypothesize that same cholesterol lowering level by routing dose of atorvastatin or lower dose of atorvastatin plus ezetimibe could achieve the same effect on coronary artery plaque cessation or regression.


Eligibility criteria:
inclusion criteria: * willing to receive the coronary angiography and potential pci therapy exclusion criteria: * patients was treated by statins before randomization * patient with ≤ 20% and ≥ 70% coronary narrowing and target lesion * st elevation myocardial infarction less than 7 days * without informed consent * abnormal liver function before randomization, (ast, alt ≥uln) * active hepatitis or muscular disease * impaired renal function with serum creatinine level \> 3mg/dl * impaired left ventricular function with lvef \> 30% * participate in other studies

Keywords: ivus coronary plaque regression
phase ⅱstudy of tyroserleutide for injection in hepatocellular carcinoma(hcc) patients

Conditions: Hepatocellular Carcinoma

Summary: the investigation is a randomized, double-blind, placebo involved and multi-center clinical trial. all subjects are assigned to 4 groups, including 3mg, 6mg, 12mg per day and placebo group. each group includes 25 subjects, who have hepatic-cellular carcinoma accompanied with branch vein thrombosis. they receive investigational drug 40 days after resection surgery. each cycle lasts 4 to 6 days with an interval of 29 days in all 6 cycles.

* patients who have signed the informed consent form and are eligible for the entry criteria will be randomly assigned to either the tyroserleutide treatment group or the placebo group. no matter which group the subject is assigned, he/she would receive chemotherapy treatment through the portal vein pump which was transplanted during the carcinoma section surgery 40 days before the randomization. * participants will be given either tyroserleutide or placebo through intravenous injection with an interval of 29 days, during which the participant will not take any investigational drug or any other anti-tumor treatment as well. on the day just next to the completion of each cycle of research treatment which usually lasts for 3-5 days, the participant will receive medical inspection so as to observe and ensure drug safety. * participants will continue to receive investigational drug for 6 cycles until being detected with recurrence or metastasis of tumor or experiencing any serious side effects. * a ct scan or mri scan will be performed for each participant to exclude the recurrence or metastasis of tumor and assess the effects of treatment once before the initiation of each new cycle.

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. age between 18 and 75 years 3. hepatocellular carcinoma accompanied with branch vein thrombosis 4. carcinoma and bolt resection integrity, cutting edge no tumor cells by microscopic lens in operation 5. cta or mri no carcinoma and bolt after operation exclusion criteria: 1. hypersensitivity to the composition similarity of investigational drug 2. concomitance other system primary tumor 3. surface area 1.47m2～1.92m2 4. hbv (-) and hcv(-) 5. patients who have received resectional surgery for hcc 6. hcc complicating main portal vein cork 7. hcc complicating hepatic vein cork 8. patients who have received systematicness therapy for hcc 9. patients who have received immunoregulant 4 weeks before randomization 10. concurrent participation in another clinical trial involving experimental treatment is excluded 4 weeks before randomization 11. uncontrolled infection, hemorrhage, guts leakage postoperative complications 12. postoperative liver function child-pugh c 13. no evidence of extra-hepatic metastases postoperative 14. no utility sample for gene chip research 15. no physical examination, laboratory and imageology examination that baseline request

Keywords: hepatocellular carcinoma recurrence
smart insoles for improving sensation, balance and mobility in people with diabetic peripheral neuropathy.

Conditions: Diabetes Mellitus; Diabetic Neuropathies; Unsteadiness

Summary: the long-term effects of vibrating insoles on improving gait, balance and peripheral sensation in people with diabetic peripheral neuropathy remain unknown. the pathfeel clinical trial will investigate the efficacy of vibratory insoles worn for ten days for enhancing sensory perception, gait quality, balance and physical activity in people with mild to severe diabetic neuropathy. the primary outcome will be changes in gait speed and postural and dynamic balance.

the path feel clinical trial will investigate the efficacy of foot sole vibration applied for 10 days during daily life for improving peripheral sensation, balance and mobility in people with diabetic peripheral neuropathy. twenty-two people with mild to severe diabetic neuropathy will perform a prospective comparison where they wear an insole system over the course of two interventional periods of 10 days each in a randomised, cross-over design, during which there will be a period where the device provides vibrational stimuli, vs a control condition where the device is worn, but provides no stimuli. any changes in activity levels, peripheral sensation, quality of life and balance control will be compared between each condition to determine the longer-term effects of foot sole vibration. each participant will undertake four study visits with periods of device use between them. participants will complete a set of questionnaires that will assess quality of life (neuroqol) and fear of falling (fes-i). measurements of the level of peripheral neuropathy will be taken at both feet using non-invasive methods, including a neurothesiometer (i.e., vibration perception threshold) and a composite score (i.e., modified neuropathy disability score). gait, postural and dynamic balance during daily activities, including walking, stair walking will be assessed through a combination of 3d motion capture system and force platforms. changes in physical activity will be quantified by accelerometry.

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes type 1 or 2 * ≥1 palpable foot pulses * presence of mild to moderate diabetic peripheral neuropathy defined by a vibration perception threshold ≥15 volts and/or mnds score ≥3. * aged ≥ 18 years * ability to walk unaided for 30 steps * able to understand the study requirements * ability to check their feet regularly (or have another person check). * able to read the study documents * fit shoe size eu 36-47.5 / uk 3.5-13. exclusion criteria: • active foot ulcer * lower limb amputation (anything more than amputation of two lesser toes) * presence of charcot deformity * dementia or other cognitive impairment * significant cardiopulmonary or other systemic disease limiting the patient's ability to walk 30 steps. * person's with bodyweight greater than 130kg (due to insole device limitations) * presence of implantable neurostimulators * presence of a pacemaker.

Keywords: smart wearable device vibration insoles gait peripheral sensation balance
a study to assess the effect of tocilizumab on signs and symptoms in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this single arm, open label study will assess the safety and efficacy, with regard to reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis. patients will receive tocilizumab 8 mg/kg iv every 4 weeks for a total of 6 infusions. patients already receiving methotrexate at entry into the study may continue with their treatment together with tocilizumab.the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients,\>=18 years of age; * rheumatoid arthritis diagnosed \>8 weeks and \<4 years prior to baseline; * naive to, or not responding well to, methotrexate; * swollen joint count \>=8 (66 joint count) and tender joint count\>=8 (68 joint count) at screening and baseline. exclusion criteria: * rheumatic autoimmune disease other than rheumatoid arthritis; * patients with functional class iv rheumatoid arthritis; * history of, or current, inflammatory joint disease other than rheumatoid arthritis, or other systemic autoimmune disorder.
study for the management of pediatric chronic rhinosinusitis with or without balloon sinuplasty

Conditions: Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis

Summary: chronic rhinosinusitis, a common diagnosis in children, remains a poorly understood disease. adenoidectomy (surgery to take out the adenoid pads- infection fighting glands in the back of the throat) is performed since the adenoid pad may trap germs that enter a child's body and can get so swollen with bacteria that they become infected themselves. functional endoscopic sinus surgery (fess) and adenoidectomy are currently the most common surgeries performed on children with this disease. another treatment is adenoidectomy and irrigation of the maxillary sinus without fess. new technology has emerged using a balloon catheter to dilate (open) the sinus passage in addition to the adenoidectomy and irrigation. this study seeks to answer if children with chronic rhinosinusitis who undergo adenoidectomy with balloon dilation of the maxillary sinus passage and irrigation experience improved quality of life outcomes compared to children with chronic rhinosinusitis who undergo an adenoidectomy with maxillary sinus irrigation without dilation of the sinus passage.


Eligibility criteria:
inclusion criteria: 1. sinonasal symptoms of at least 12 weeks' duration or recurrent sinusitis \>3x/year 2. failure to respond to 3-week course of antibiotic and 3 month course of nasal steroid preparations or antihistamines as well as saline nasal irrigation 3. rhinosinusitis documented by ct scan following oral antibiotic course. computer tomographic findings considered to be consistent with sinusitis include partial or complete sinus opacification. allergy and immunology workup will be recommended on an individual basis - exclusion criteria: 1. patients with extensive sinonasal polyps, extensive sinonasal osteoneogenesis, sinonasal tumors 2. history of facial trauma that distorts sinus anatomy 3. ciliary dysfunction 4. pregnancy will be excluded. 5. patients with cystic fibrosis, craniofacial anomalies, metabolic disorders, or immunodeficiencies 6. patients who have had their adenoids removed and thus may be candidates for functional endoscopic sinus surgery will also be excluded. 7. patients with a history of sinus surgery or significant anatomic abnormalities on ct scan that would require endoscopic sinus surgery or septoplasty would also be excluded. of note, children who will be undergoing concurrent surgeries will not be excluded. -

Keywords: pediatric chronic rhinosinusitis